Free Trial

CVS Health (CVS) Stock Forecast & Price Target

$61.01
+2.36 (+4.02%)
(As of 07/26/2024 ET)

CVS Health - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 23 Wall Street analysts who have issued ratings for CVS Health in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 10 have given a hold rating, and 13 have given a buy rating for CVS.

Consensus Price Target

$75.05
23.01% Upside
High Forecast$100.00
Average Forecast$75.05
Low Forecast$58.00

According to the 23 analysts' twelve-month price targets for CVS Health, the average price target is $75.05. The highest price target for CVS is $100.00, while the lowest price target for CVS is $58.00. The average price target represents a forecasted upside of 23.01% from the current price of $61.01.

TypeCurrent Forecast
7/28/23 to 7/27/24
1 Month Ago
6/28/23 to 6/27/24
3 Months Ago
4/29/23 to 4/28/24
1 Year Ago
7/28/22 to 7/28/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
13 Buy rating(s)
12 Buy rating(s)
14 Buy rating(s)
Hold
10 Hold rating(s)
10 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$75.05$75.05$89.44$105.11
Forecasted Upside23.01% Upside20.74% Upside21.54% Upside24.03% Upside
Get CVS Health Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CVS and its competitors with MarketBeat's FREE daily newsletter.

CVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

CVS Health Stock vs. The Competition

TypeCVS HealthRetail/Wholesale CompaniesS&P 500
Consensus Rating Score
2.57
2.45
2.50
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside23.01% Upside52.26% Upside9.09% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/23/2024Cantor Fitzgerald
3 of 5 stars
S. James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$58.00 ➝ $58.00+0.94%
5/30/2024Baird R W
0 of 5 stars
M. Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
5/30/2024JPMorgan Chase & Co.
3 of 5 stars
 Lower TargetOverweight ➝ Overweight$101.00 ➝ $86.00+53.54%
5/30/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$61.00+13.55%
5/8/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Graja
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$100.00 ➝ $80.00+44.85%
5/7/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$76.00 ➝ $60.00+6.88%
5/7/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$99.00 ➝ $59.00+5.41%
5/2/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$95.00 ➝ $77.00+41.73%
5/2/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$85.00 ➝ $74.00+36.08%
5/2/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$78.00 ➝ $63.00+16.90%
5/2/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$90.00 ➝ $66.00+21.37%
5/2/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$86.00 ➝ $72.00+27.84%
5/2/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$85.00 ➝ $60.00+6.53%
5/1/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
5/1/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Market Perform$87.00 ➝ $60.00+5.60%
3/15/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$93.00 ➝ $94.00+21.75%
2/8/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$86.00 ➝ $84.00+11.24%
12/22/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$94.00+19.56%
11/2/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$110.00 ➝ $100.00+43.55%
10/10/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$93.00 ➝ $80.00+11.41%
9/19/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeIn-Line ➝ Outperform$81.00 ➝ $83.00+17.40%
9/12/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradePeer Perform ➝ Outperform$80.00+16.36%
8/17/2023Edward Jones
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
8/4/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$90.00 ➝ $85.00+14.34%
5/8/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$125.00 ➝ $96.00+35.82%
4/10/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold
2/9/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$130.00 ➝ $143.00+60.75%
8/17/2022Tigress Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$125.00 ➝ $130.00+23.69%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:32 AM ET.

CVS Forecast - Frequently Asked Questions

What is CVS Health's forecast for 2024?

According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for CVS Health is $75.05, with a high forecast of $100.00 and a low forecast of $58.00.

Should I buy or sell CVS Health stock right now?

23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CVS Health in the last twelve months. There are currently 10 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CVS shares.

Does CVS Health's stock price have much upside?

According to analysts, CVS Health's stock has a predicted upside of 20.98% based on their 12-month stock forecasts.

Has CVS Health been upgraded or downgraded by Wall Street analysts recently?

Over the previous 90 days, CVS Health's stock had 4 downgrades and 1 upgrade by analysts.

What analysts cover CVS Health?
Do Wall Street analysts like CVS Health more than its competitors?

Analysts like CVS Health more than other "retail/wholesale" companies. The consensus rating for CVS Health is Moderate Buy while the average consensus rating for "retail/wholesale" companies is Hold. Learn more on how CVS compares to other companies.


This page (NYSE:CVS) was last updated on 7/27/2024 by MarketBeat.com Staff

From Our Partners